This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Eli Lilly & Company
Drug Names(s): CS-747, LY640315, Prasugrel, Efient (EU)
Phase III results showed no improvement over placebo. The trial was a failure and with no other ongoing studies, BioMedTracker is suspending this drug and we are deleting any forecasted revenues in our model.
Prasugrel is an antiplatelet agent designed to prevent platelet activation and aggregation by blocking adenosine diphosphate receptors on the platelet surface.
Deal Structure: Effient was discovered by Sankyo and Ube Industries. In December 2000, Eli Lilly and Sankyo signed a letter of intent to collaborate on Effient. Under the letter of intent, Sankyo will receive a signing fee, milestone payments and royalties on product sales. Lilly and Sankyo will co-promote the product in the United States. For the remaining global market, Lilly and Sankyo will jointly market the product except for certain countries where Lilly will receive exclusive sales and marketing rights. Lilly and Sankyo will share in the development of the compound and plan to manufacture the finished product. Ube will manufacture the bulk material.
Partners: Daiichi Sankyo Co., Ltd.
Pink Sheet Effient FDA Reviewers
Pink Sheet Effient Clinical Development
Additional information available to subscribers only: